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A social ecological model (SEM) to exploring barriers of and facilitators to the 
implementation of Opioid Agonist Treatment (OAT) programmes in prisons
Introduction
Opioid agonist treatment (OAT), an evidence-based treatment for opioid dependence, 
has been associated with reductions in illicit drug use, injecting drug use, the sharing 
of injecting equipment and an increase in adherence to antiretroviral therapy (ART) 
(Springer and Bruce 2008; Wolfe et al. 2010; Hedrich et al. 2012). OAT in prisons 
therefore, plays a significant role in preventing human immunodeficiency virus (HIV) 
and Hepatitis C virus (HCV) transmission through the reduction of unsafe injecting 
practices (Kinner et al. 2013; Jürgens et al. 2009; Azbel et al. 2018). However, despite 
its proven effectiveness, the availability and coverage of prison OAT programmes 
remain low. By 2016, only 80 out of 158 countries, where injecting drug use was 
reported, had implemented OAT programmes (Harm Reduction International 2016). 
OAT implementation in prisons was even lower. Only 29 countries provided such 
programmes in 2008 (Larney 2009).
1.HIV/AIDS issues and the Indonesian responses
Studies show that prisoners, especially injecting drug users, are at greater risk of 
exposure to HIV infection in prison settings (Larney et al. 2017; Altice et al. 2016). 
These risks are linked to continuing injecting drug use and the practice of sharing un-
sterile injecting equipment in prisons (Izenbergh 2014; Zamani et al. 2010). Indonesia 
is witnessing a concentrated HIV epidemic with a prevalence rate of 29% among 
injecting drug users (UNAIDS 2018). In 2008, it was estimated that there were 3.4 
million people who use drugs in Indonesia, of whom 7% inject drugs, with heroin 
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among the most commonly injected drugs (National Anti-Narcotics Agency of the 
Republic of Indonesia 2009). In 2010, the Indonesian Ministry of Justice (MOJ) found 
that HIV prevalence rates in the prison population ranged from 8% in general prisons 
to over 33% in narcotics prisons (Directorate of Corrections 2010). This variation 
perhaps reflects the different types of prison in Indonesia (narcotics and general 
prisons) and their location (urban and rural). Studies have reported increasing 
numbers of HIV cases associated with injecting drug use in Indonesian prisons from 
37.6% in 2010 (Nelwan et al. 2010) to 56 % of cases in 2015 (Culbert et al. 2015). The 
latter study also found that 94.5% of prisoners with HIV reported sharing contaminated 
injecting equipment (Culbert et al. 2015).
In response, the Indonesian government launched HIV/AIDS prevention programmes 
including OAT programmes in both community and prison settings. Indonesia was also 
the first Asian country to include prisons within its Strategic Plan (Directorate of 
Corrections 2005). However, unlike in community settings, Indonesian prisons did not 
adopt needle and syringe programmes (NSPs) on safety and moral grounds. The first 
OAT programmes were established in a community hospital in Bali in 2003 (National 
AIDS Commission 2009), while the first prison OAT programmes were introduced in 
Kerobokan prison (also in Bali) in 2005, with methadone as the only drug offered 
(Ministry of Health Indonesia 2008). 
Imprisonment as a response to drug use is common in many Asian countries 
(Degenhart et al. 2010; Mustafa in press), including Indonesia. Although Narcotics Law 
No. 35 of 2009 supported the provision of medical and social rehabilitation for people 
who use drugs, the criminalisation of drug users has increased after a new law was 
passed in 2012 that imposes severe penalties on drug offenders (Narcotics Law No. 
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35 of 2009). Therefore, alleged and convicted drug users are commonly imprisoned. 
This has resulted in severe overcrowding, with some prisons running at 260% capacity 
(Directorate of Corrections 2016). 
Drug law enforcement policy and the massive incarceration of drug users has 
negatively affected the availability of, and access to, OAT programmes as indicated in 
other countries (Kamarulzaman 2009a; Hayashi et al. 2017). By 2016, 12 out of 412 
Indonesian prisons had established OAT programmes, however, the overall uptake 
was very low and only served an estimated 69 prisoners in 2016 (Directorate of 
Corrections 2017). A US study by Friedmann (2012) reports that low uptake of OAT 
programmes in prisons is often associated with negative attitudes among prison staff, 
safety concerns, a drug-free treatment philosophy in prisons, as well as a lack of 
resources.
Little is known about the delivery of OAT programmes in Indonesian prisons. This 
qualitative study aimed to understand the role of Indonesian OAT programmes in the 
context of HIV prevention programmes by using the social ecological model (SEM) as 
an analytical lens. The study comprised three different Indonesian prisons and 
incorporated  interviews with prison governors, security staff, healthcare staff and 
prisoners. It provides an in-depth understanding of the barriers to and facilitators of 
the delivery of programmes at the intrapersonal, interpersonal, and social-structural 
levels in this middle-income country setting.
2.Social Ecological Model (SEM) 
As noted, this study employed the SEM model that examines interdependences 
between intrapersonal, interpersonal, institutional, community factors and public policy 
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(McLeroy et al. 1988). This model has been previously applied in research into HIV 
risk behaviours among people who inject drugs because of its holistic approach and 
recognition of the complexity of personal and social circumstances (Mburu et al. 2019). 
The model allows for the exploration of multiple contributing factors to complex 
situations and for the identification of potential strategies for improvement in these 
settings  (Gombachika 2012; Baral et al. 2013). This study drew on the SEM model in 
order to incorporate multilevel analyses and to understand what types of interventions 
might mitigate barriers to the implementation of OAT programmes in prisons.
Setting
Indonesia was chosen for this study due to the high prevalence of drug use and HIV 
in prisons mentioned above. Indonesian prisons are classified by security levels, 
whichrange from low to maximum security; prisoner gender (male or female); age 
(children, youth, or adult), and offense (narcotics or non-narcotics prisons). In 2016, 
there were 33 narcotics prisons out of  a total estate of 412 prisons (Directorate of 
Corrections 2017).
The Ministry of Justice and Human Rights (MoJ) supervises prisons, while the Ministry 
of Health (MOH) and external agencies, such as international or local non-
governmental organisations (NGOs), mainly support the delivery of HIV/AIDS 
programmes in prisons. At the time of the study in 2016, only methadone was 
prescribed in Indonesian OAT programmes. 
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Methods
Design and sampling methods
The importance of understanding cases within their specific contexts is the primary 
concern of a case study (Stake 2005). A qualitative case study approach was adopted 
in this study to provide an in-depth exploration of the complexities of prison settings 
and their influence on the delivery of methadone programmes. 
Three prison settings were selected for the case study in the capital city of Indonesia, 
Jakarta.  Their selection was based on numbers of drug users, prevalence of HIV 
infection and the availability of methadone programmes. The final sample included a 
narcotics prison with a methadone programme, a general prison with a methadone 
programme and a general prison with no methadone programme.  The number of 
prisoners  receiving methadone in the two study prisons  where OAT was available 
was  17 and  45 participants,  out of approximately 2300 and 2600 prisoners, 
respectively. This approach allowed for an in-depth comparison between the settings 
and for any essential differences to be highlighted.
Potential eligible participants were recruited in each prison through purposive 
sampling, with the help of the chief of security and healthcare staff.  Snowball sampling 
was also employed to minimise participant selection bias. 
Selection criteria for study participants
Prison staff participants were selected based on their current roles and responsibilities. 
Methadone prisoners were selected based on their participation in the methadone 
programme, while non-methadone prisoners were selected if they were current 
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injecting drug users or had injected drugs for more than six months prior to their 
incarceration. 
Ethical approval and consent to participate
The study received ethical approval from the University Research Ethics Committee, 
University of Stirling. There are no procedures for gaining ethical approval from the 
Indonesian Ministry of Justice and Human Rights (MoJHR). To obtain access to the 
prison service, a letter of recommendation from the MoJHR was first obtained and sent 
to each of the prisons selected as potential study sites. An approval letter giving 
permission to access the study prisons was then signed by each of the three prison 
governors. 
Both written and verbal consent regarding their willingness to participate in the study 
were obtained from each participant prior to interview. Time was taken over this 
process to ensure that participants were not coerced and no monetary incentives were 
offered. Protecting the confidentiality of both study participants and the prisons 
involved in the study was a priority. Therefore, no identifying information that could 
lead to any potential harm to individuals or to the reputations of the prisons, was 
disclosed in any reports, or to any other party including the prison authorities.
Data collection
In-depth face-to-face interviews were employed to collect data for this study and took 
place between December 2015 and March 2016. Interviews were conducted with a 
range of prison stakeholders including prison governors, security staff, healthcare staff 
and both methadone and non-methadone prisoners.
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Interviews were conducted in a private room or convenient place for the participant. 
Bahasa Indonesian, the official language of Indonesia, was used in all interviews. Four 
topic guides were developed based on the study themes for each group to allow 
comparison across sub-groups and prisons. The investigator (first author) translated 
these guides from Indonesian to English and conducted back-translation from English 
to Indonesian. All interviews were recorded digitally, except for one with a prisoner 
and one with a staff member. Hand-written notes were taken in these cases. The 
interviews lasted for between 30 minutes and 120 minutes. In total, 57 interviews were 
completed: 3 prison governors, 9 security staff, 10 healthcare staff (including doctors, 
nurses, and a psychologist), 16 methadone prisoners, and 19 non-methadone 
prisoners. The total number of prisoner participants in each prison was 17 prisoners 
in the narcotics methadone prison, 12 prisoners in the general methadone prison, and 
6 prisoners in the general non-methadone prison. Table 1 below gives details of the 
characteristics of the prisoners who participated in the study. 
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Table 1. Prisoner characteristics
Data analysis
The recordings of the interviews were transcribed anonymously and translated into 
English. The transcripts were then coded and analyzed using Nvivo 11 (Brandão 
2015). Framework analysis was adopted for this study because of its transparent 
approach to organising data (Ritchie et al. 2014), while further thematic analysis 
(Braun and Clarke 2006; Mustafa 2021) was also undertaken. An initial thematic 
framework was created by identifying key issues, concepts, and themes. The analysis 
started with the construction of a descriptive account by identifying similarities and 
differences across cases and within individual cases to identify how the programmes 
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worked across systems, together with the identification of similarities and differences 
across both individual and prison cases. This was followed by seeking explanatory 
accounts by exploring relationships through mapping connections between categories 
and searching for explanations within the whole data set.  Guided by the social ecology 
model (Mburu et al 2019), identified facilitators of and barriers to the implementation 
of OAT programmes in prisons were mapped onto intrapersonal, interpersonal, and 
organisational factors, as indicated in figure 1.
Figure 1. Social-ecological model of OAT programmes in prisons
This model is modified from the  social-ecological influences of HIV risk  (Mburu et al 
2019).
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Findings
Intrapersonal-level factors facilitating the delivery of OAT programmes 
Perceived benefits of OAT programmes in prison
Both prison staff and prisoners across the three prisons reported the benefits of 
providing OAT programmes in prisons. For many prison officers, the benefits of the 
programmes included a reduction in the number of heroin users that regularly inject 
the drug and a contribution to the management of prisoners:
“Since we have been giving prisoners methadone, they do not need heroin 
anymore. As far as I know, HIV infection is caused by unsterile needles and 
syringes when using heroin and, so, HIV transmission was reduced here"
(Narcotics methadone prison, Prison officer, late 20s).
“Prisoners withdrawing from heroin can be a source of disturbance to others 
and can cause chaos in their cell because of the need for drugs. Being on 
methadone makes them less tense" 
(Narcotics methadone prison, Prison officer, mid 20s)
Both methadone and non-methadone prisoners believed that OAT programmes could 
bring several health benefits to methadone prisoners, including reductions in the use 
of injecting equipment and improvements in their quality of life including in their 
physical, social, financial and mental health conditions. A non-methadone prisoner in 
the narcotics methadone prison commented on the consequent reduction in the 
amount of injecting equipment around and how this affected his feelings towards 
methadone prisoners:
“They used to share syringe needles that cause HIV transmission, and I used 
to worry about stepping on needles, but now I feel no worries since I do not 
see any syringe needles here. I do not worry about getting HIV infection, and 
I feel more relaxed and safer around them" 
(Narcotics methadone prison, Non-methadone prisoner, mid 30s).





























































International Journal of Prisoner Health
11
Methadone-prisoners from both methadone prisons also noted benefits: 
“I found out that methadone brings positive effects to my life -physical and
    emotional- so there were no reasons why I should decline the methadone”
(General methadone prison, Methadone-prisoner, late 30s).
"We can build a better familial relationship; my family members used to hate 
me, but now we are tight as a family" 
(Narcotics methadone prison, Methadone-prisoner, mid 30s).
”Since methadone is free, so I would not spend money to buy heroin or ask 
my family for financial support” 
(Narcotics methadone prison, Methadone-prisoner, early 40s).
The importance of the latter should not be under-estimated in prisons in lower middle 
income countries such as Indonesia where prisoners require money for many 
purposes, including the purchase of adequate food.  Overall, however, there were 
more substantial barriers than facilitators identified to the delivery of OAT 
programmes in the prisons studied.
Intrapersonal-level barriers to the delivery of OAT programmes
Interviews suggest that intrapersonal barriers related to misperceptions concerning 
HIV tranmission and the harm reduction role of OAT programmes, as well as concerns 
around methadone dependency and withdrawal symptoms. 
(Mis)perceptions relating to HIV tranmission in prison 
Many prison staff, across all three prisons, talked about the low risk of HIV tranmission 
in prison. They perceived that the number of injecting heroin users in prisons was 
small, that heroin was not widely available and that there was a greater awareness 
among prisoners of injecting as a risk behaviour for HIV transmission. As the following 
quote from a senior member of staff illustrates, prison staff’s understanding of HIV 
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transmission risks was limited to heroin injection and heroin was perceived to be 
unavailable:
“What I have heard is that the number of people who inject heroin has 
decreased. It (injecting drugs) is an unpopular method among drug users 
because they know the risks of doing it. They also say heroin is very rare 
nowadays” (Prison governor).
A prisoner in the narcotics methadone prison provided an explanation for this 
(mis)perception that few prisoners were injecting drugs:
"Only the small number of prisoners in the methadone programme are 
known to the health staff as injecting heroin users, but most of the people 
who use heroin are unidentified here" 
(Narcotics methadone prison, Non-methadone-prisoner, early 30s).
A prisoner from the narcotics methadone prison also indicated that there is an 
abundant supply of affordable heroin in prison:
“There is much heroin…[and], the price of heroin is much lower than 
methamphetamine" 
(Narcotics methadone prison, methadone-prisoner, early 30s).
 
Furthermore, understanding the risks associated with injecting was not sufficient to 
prevent prisoners from injecting drugs. The degree to which injecting drugs was given 
priority over the known risks was indicated by a prisoner from the general non-
methadone prison:
"The most important thing people will look for in prison is drugs. I could not 
refrain from taking heroin. It is my greatest need to inject drugs, so I cannot 
hold back, even though I know the risks of injecting drugs" 
(General non-methadone prison, non-methadone prisoner, late 20s).
(Mis)perceptions of the harm reduction role of OAT programmes
The majority of the healthcare staff, and some prison officers in the two methadone 
prisons, showed a relatively good understanding of the aims of the programmes. For 
example, a member of the healthcare staff commented:
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"Methadone programmes are effective programmes considering their aims, 
since previously there was much heroin and the number of heroin users was 
up to 20%. The low level of injecting drug users has only happened recently. 
I think it is better for them to use methadone instead of injecting heroin"  
(Narcotics methadone prison, Doctor, female).
Another explained: 
“Prisoners who use heroin typically inject the drug. That is why we have 
methadone to prevent diseases related to unsafe injecting practices including 
HIV/AIDS” 
(General methadone prison, Doctor, male).
In contrast, with a very few exceptions, healthcare staff in the general non-methadone 
prison seemed not to recognise the potential risks associated with injecting 
behaviours in prison. Instead, methadone programmes were considered a lower 
priority than achieving a drug-free state.
"Some prisoners who took methadone in other prisons and they were being 
transferred to this prison, could cope with the methadone withdrawal 
symptoms and have a normal life without methadone and illegal drugs here" 
(General non-methadone prison, Healthcare staff, female, early 30s).
Furthermore, across all three prisons, many of the non-methadone prisoners, prison 
officers and prison governors did not fully understand that methadone programmes 
had been implemented in Indonesian prisons as part of an HIV prevention strategy. 
Instead they believed that methadone was provided merely to treat cravings for 
heroin: 
“I think methadone cannot prevent HIV transmission, and it is only a drug to 
prevent people from heroin withdrawal" 
(Narcotics methadone prison, Non-methadone prisoner, mid 30s).
A common misconception among prison staff was that providing methadone was 
equivalent to providing an illegal drug. Rather surprisingly even one doctor subscribed 
to this view:
 “If we provide methadone, it means we provide illegal drugs since 
methadone is a heroin replacement”
 (General non-methadone prison, Doctor, female).
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 Similarly, a prison governor said:
 “Methadone is not good as it means letting the prisoners use illegal drugs”
 (Prison governor).
Concerns about methadone dependency and withdrawal symptoms 
The majority of prisoners in all three prisons expressed concerns about methadone 
dependency and withdrawal symptoms, which were often regarded as more severe 
than heroin dependency and withdrawal. Methadone was seen as a “harder”, more 
harmful drug than heroin and one that was difficult to stop using. These findings 
suggest that there is a lack of information about methadone as a medical treatment 
to support reducing heroin dependence: 
"The methadone causes heavy drug dependency compared to heroin" 
(General methadone prison, Non-methadone prisoner, mid 20s).
"Methadone is pure heroin, so its effects are devastating, while our heroin is 
only dregs of heroin"
 (General methadone prison, Non-methadone prisoner, early 30s).
"No, I am not interested in taking methadone as it leads to greater damage 
to health and makes death come even faster"
 (Narcotics methadone prison, Non-methadone prisoner, late 20s).
"It is difficult to stop methadone because the methadone has been in our
      body for too long, so it needs time to neutralise the methadone. My friend
was at 5mg methadone, but still found it hard to stop " 
(Narcotics methadone prison, Methadone-prisoner, mid 30s).
The views of family members reinforced these concerns:
"My family is concerned about methadone because it is like he oin, so that I 
will end up as methadone dependent"
 (General methadone prison, Methadone-prisoner, early 30s).
Concerns about methadone dependency were also reported by some healthcare staff 
from the general non-methadone prison:
"We (healthcare staff and prison authorities) had a meeting about 
methadone, and we (healthcare staff) claimed that the methadone 
programmes are useless because it makes the prisoners become drug 
dependent on methadone” 
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(General non-methadone prison, Healthcare staff, female, early 30s).
Fear of methadone withdrawal led both to a fear of death and a fear of witnessing 
death. These fears increased the perceived degree of risk associated with 
participation, as one prisoner from the narcotics methadone prison put it:
“Many prisoners were afraid to watch the effects of methadone withdrawal 
on their fellow prisoners. Even if they took 10-20 showers, the symptoms 
were not reduced for two months. This is quite different with heroin 
withdrawal effects which are over within a week”
(Narcotics methadone prison, Methadone prisoner, mid 30s).
The belief that methadone withdrawal can result in death was common in both 
methadone prisons. This belief stems from either personal or others’ experiences of 
seeing prisoners, friends and relatives die. Indeed, most of the prisoners, whether 
they were taking methadone or not, expressed concerns about dying from 
methadone: 
“Nine out of 10 prisoners would encourage us to stop attending the 
programme and warn about painful methadone withdrawal symptoms that 
lead to death" 
(Narcotics methadone prison, Methadone-prisoner, early 40s).
“One of the prisoners died the following day after taking methadone, and that 
traumatised me. Most of my friends who come together to this prison have 
died in this prison because of that methadone. All of them died here. Thanks 
to God I am still alive [because I do not take methadone]" 
(Narcotics methadone prison, Non-methadone prisoner, early 30s).
While healthcare staff from the narcotics methadone prison indicated that 
opportunistic infections relating to HIV were often the underlying cause of death, the 
sight of corpses in the clinic corridor in the narcotics methadone prison and the 
emotional reactions of bereaved family members, heightened fears. A methadone-
prisoner described a traumatic scene:
“I feel afraid because I have seen too many dead bodies. It frightened me. 
You know that it was like yesterday, they put the deceased outside (in the 
clinic corridor), so we could see him, and his relatives came and how they 
reacted to that. I do not know how to describe my feelings at that time" 
(Narcotics methadone prison, Methadone-prisoner, early 40s).
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Apparently, the corpse was that of an HIV patient who had been hospitalised in the 
clinic treatment room. The staff, who did not consider how the other prisoners might 
react, had moved the corpse to the corridor for removal by his family since the prison 
had no specific room for storing corpses.  Such fears were reinforced by a lack of 
medical support during withdrawal:
“I would experience methadone withdrawal symptoms alone at night 
because the cell was locked. Other prisoners and the prison officers 
considered it as an unthreatening condition, so we had to wait until the 
following morning to increase our methadone dose” 
(General methadone prison, Methadone-prisoner, mid 20s).
Similarly, others raised concerns relating to the lack of access to methadone while in 
the segregation unit and limited access to methadone in other prisons:
“Some methadone-prisoners had experienced severe methadone 
withdrawals because there is no methadone in this prison, and then they 
were being sent back to their original prison (where methadone programmes 
are available)” 
(General non-methadone prison, Non-methadone prisoner, early 30’s)
Interpersonal processes-level barriers to the delivery of OAT programmes
Interpersonal factors refer to wider availability of drug and inflexible treatment 
processes in prisons. These factors, together with  negative messages received from 
healthcare staff and the negative influence of peers, friends and family members, 
weakened support in enhancing the effectiveness of OAT programmes and in 
supporting implementation and delivery efforts in prisons.
Widespread availability of illicit drugs in prison
Drug consumption is influenced by the availability of drugs; supply, therefore, is 
a major driver of drug use in prison. As one prisoner from the general non-
methadone prison observed: 





























































International Journal of Prisoner Health
17
"Several people are taking illicit drugs [heroin] here, so I started craving, but 
for example, if there were no drugs here, I would forget about taking them" 
(Narcotics methadone prison, Non-methadone prisoner, late 20s).
Another prisoner  noted:
“My friends told me it is easy to get illegal drugs in prisons. In every unit, you 
can find them” 
(General non-methadone prison, Non-methadone prisoner, mid 30s).
Many prisoners in all three prisons identified the easy availability of drugs as a 
significant driver of both prisoners’ initiation into use or relapse back to drug use: 
"Dealing with cravings for heroin was difficult particularly when you saw your 
cellmate taking those drugs" 
(Narcotics methadone prison, Non-methadone prisoner, late 20s).
A further explanation for the availability of drugs in prison was staff low pay, a point 
that foregrounds the general lack of resources in the Indonesian prison system:
"We conduct raids, but as the staff are also human beings, they are tempted 
by the prisoners. The most challenging task here is to supervise staff. If some 





In the narcotics methadone prison, prisoners who reported that they had been heroin-
free for more than three months were ineligible for OAT programmes since the 
healthcare staff thought they had fully recovered from their drug dependence. 
Futhermore, the narcotics prison also required family consent for entry into the 
programme there, as mentioned above.  This requirement was justified in terms of 
increasing the understanding that prisoners’ families had of the programmes. 
However, many prisoners viewed the requirement as a way of avoiding legal liability:
“The doctors were afraid that something bad might happen to them 
[methadone patients], so their family need to also be responsible for their 
condition” 
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(Narcotics methadone prison, Non-methadone prisoner, late 30s).
In addition, some prisoners could not contact their family members as  doing so would 
reveal their HIV and heroin use status. Many had had no contact with their families 
for some time for this very reason: 
“It is hard to bring our family members here since we are unable to contact 
them” 
(Narcotics methadone prison, Non-methadone prisoner, late 20s).
“They do not want their family members to know they are taking heroin. You 
know that they [family members] will think you are sick (have HIV)" 
(Narcotics methadone prison, Non-methadone prisoner, early 30s).
Similarly, a member of healthcare staff from the general methadone prison 
recognised the problem of contacting family members in more general terms:
“If they are rejected for the programmes because of lack of family consent, 
then they become more deeply involved in drugs [and] that causes harm for 
other prisoners” 
(General methadone prison, Doctor, male).
Assessment processes
Further barriers related to assessment processes prior to entry onto a programme. In 
theory, doctors would assess each prisoner’s level of opioid dependence and any 
related risk behaviours. In practice however, priority was given to prisoners with 
positive drug tests in both prisons with methadone programmes:
“We could not give methadone to those with the negative urine test results 
since we supposed that they had been clean” 
(General methadone prison, Doctor, male).
Paradoxically, this approach may have had the effect of increasing the use of illicit 
drugs in prison. As one prisoner from the narcotics methadone prison explained:
“The effects of illegal drugs disappear after 3-4 days, so if you want to join 
the programmes then you should take heroin every 1-2 days before visiting 
a doctor” 
(Narcotics methadone prison, Methadone prisoner, mid 30s)
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At the same time, many prisoners in both methadone prisons felt that assessment 
processes which included sensitive questions on risk behaviours would discourage 
many prisoners from applying to join the programmes:
"Prisoners asked when they took drugs for the last time were frightened. 
They were afraid that they would be also reported to prison authorities" 
(General methadone prison, Methadone-prisoner, late 30s).
There were also concerns about the quality of the information provided about 
methadone at assessment and the lack of follow-up of prisoners referred by 
healthcare staff:
“A healthcare member staff did not explain anything about methadone’s 
adverse effects. So, I am surprised with what is happening to me 
[experiencing methadone physical adverse effects] and I want to quit taking 
methadone” 
(General methadone prison, Methadone-prisoner, early 30s).
"I told a nurse that I did methadone while I was in detention, but I did not 
have any reference letter (from the detention centre). So, I just waited but I 
never got the confirmation for methadone programmes enrolment” 
(General methadone prison, Non-methadone prisoner, mid 20s).
Dispensing practices 
In the general methadone prison, the clinic would usually open at 8.30am or 9.00am 
and close about 30 minutes later. In the narcotics methadone prison, the clinic would 
usually open at 10.00am. The staff required all methadone patients to be gathered 
together before dispensing commenced. Most of the methadone-prisoners in the 
general methadone prison had concerns about the early opening times:
 “My friend did not get methadone because he overslept and then found 
that the clinic was already closed” 
(General methadone prison, Non-methadone prisoner, mid 20s)
In contrast, in the narcotics methadone prison, the methadone-prisoners expressed 
concern at the later (10.00am) opening time, especially for those with additional 
health needs, for example, prisoners who had HIV or TB: 
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“I hope the opening hours can be moved earlier to 8.30 or 9.00am. I am also 
taking ART so when I wake up, I feel pains”
 (Narcotics methadone prison, Methadone-prisoner, early 30s).
Late opening times at weekends were another concern for prisoners from both 
prisons with methadone programmes. A methadone-prisoner from the general 
methadone prison noted: 
"At the weekends, the healthcare staff are often late, so the methadone clinic 
opens at 11 am instead of 9 am" 
(General methadone prison, Methadone-prisoner, mid 20s).
Such factors were not generally recognised as problematic by healthcare staff. Only 
one member of the hea thcare staff from the general methadone prison recognised 
that such factors might contribute to the low uptake of the programmes:
"We can see that most of the methadone participants [here] were the 
referred patients from methadone programmes in detention centres, only a 
few of the patients were originally from this prison. I do not know whether the 
issues are in the opening times, staff attitudes or something else" 
(General methadone prison, Healthcare staff, female, early 30s).
Prisoners who had decided not to join the programmes and methadone-prisoners 
both complained about the need to attend the clinic daily. A prisoner from the general 
methadone prison raised two issues: boredom and the need to raise income:
"I felt bored at having to come to the clinic every day and to wait longer 
before all getting together to get the methadone. I am a recidivist, and no 
one supports me financially. I have to focus on generating income"
(General methadone prison, Methadone prisoner, early 30s).
Many methadone-prisoners were also critical that while the dispensing practices were 
not organised around their needs, there were still consequences if they arrived late. 
These consequences included carrying out unpleasant menial tasks, urine drug 
testing and their methadone being delayed. Prisoners from the general methadone 
prison explained:
"If we came at 09.01 instead of at 09.00 am, we were told to clean the toilets" 
(General methadone prison, Methadone-prisoner, early 30s).
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“Their methadone was given in the afternoon as a punishment, so the 
methadone-prisoners could feel the withdrawal symptoms first before getting 
their methadone dose” 
(General methadone prison, Methadone prisoner, mid 30s).
Another methadone-prisoner from the narcotics methadone prison recounted:
“Once we came late, my friend was questioned and threatened with urine
testing. I was afraid, so I chose not to take methadone that day" 
(Narcotics methadone prison, Methadone-prisoner, early 30s).
Institutional process-level barriers to the delivery of OAT programmes
Almost all the prisoner participants pointed to organisational barriers to the delivery 
of methadone in prisons. 
General lack of resources
Many prisoners reported further negative effects on methadone programmes of the 
general lack of resources in Indonesian prisons, pointing to low staffing levels and to 
the lack of health education and training, of psychosocial support services and of basic 
facilities for prisoners. 
Staffing issues
The problems of delivering the programmes in such under-staffed settings led to a 
shortage of healthcare staff to dispense methadone at the weekend in both methadone 
prisons. A member of the healthcare staff from the narcotics methadone prison 
emphasised:
“There were 60-65 methadone-prisoners, and they were fighting for such 
simple things such as obtaining their medical files. I was the only woman in 
the clinic that weekend and, so, I locked the door and called the security 
staff" 
(Narcotics methadone prison, Healthcare staff, female, early 30s).
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A prison officer from the general non-methadone prison also described the gravity of 
this situation:
"There are no healthcare staff at night. So many prisoners have died here 
because of a lack of treatment. We could do nothing because we have no 
idea how to deal with prisoners who are withdrawing from drugs" 
(General non-methadone prison, Prison officer, early 30s).
Another issue was methadone diversion. Prisoners and prison staff often highlighted 
a lack of healthcare staff supervision:
"After taking methadone, he [another prisoner] went to the toilet in the clinic 
to spit out the methadone. The staff did not watch over us, so you can always 
play these kinds of tricks" 
(Narcotics methadone prison, Methadone-prisoner, early 40s).
A healthcare staff member explained:
“The staff sometimes get bored and become careless, although we have a 
rule,  ...for example, after the prisoners have drunk the methadone, we 
should talk to them to make sure that they have swallowed it, but yes… 
sometimes the staff forget that " 
(Narcotics methadone prison, Doctor, female).
Lack of education and training
Many prison officers in all three prisons also commented on a lack of training in health-
related issues. An officer from the narcotics methadone prison observed: 
“I did not get any TB or HIV information sessions from the MOJ. HIV-related 
issues were only discussed with other prison officers or prisoners” 
(Narcotics methadone prison, Prison officer, late 20s). 
However, interviews with others suggested that the MOJ or MOH provided bi-annual 
or annual training in health-related issues for some prison officers. Healthcare staff in 
all three prisons also provided monthly education sessions for prison officers, but it 
seemed that many prisoners did not or could not attend these sessions:
"I think it would be difficult if it was the healthcare staff here who conducted 
the training (in prisons). We (prison officers) might not be interested in 
coming since we also have other tasks” 
(General methadone prison, Prison officer, late 20s).
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It also appeared that information about methadone was provided only as an addition 
to education sessions for HIV-infected prisoners:
"I got two HIV education sessions while I was here. They also talked a little 
bit about the aims of methadone, but [the information] was not clear to me" 
(General methadone prison, Non-methadone prisoner, early 30s).
Psychosocial support services
Unlike HIV-positive prisoners, drug-addicted prisoners rarely received psychosocial 
support. A member of healthcare staff from the general methadone prison believed 
that such problems for prisoners with addictions were insignificant and that they 
[health-care staff] were, in any case, not the right people to provide such support:
"Some methadone-prisoners sometimes take illicit drugs to deal with their 
personal problems, but that kind of situation only occurred occasionally, and 
mostly they would hesitate to talk about that problem with us" 
(General methadone prison, Doctor, male).
In contrast, a methadone prisoner recognised his need for such services to deal with 
previous traumatic experiences: 
“I have traumatic experiences of friends’ and family deaths related to 
methadone withdrawal and I need to talk about these problems” 
(General methadone prison, Methadone-prisoner, early 30s).
Lack of basic facilities for prisoners 
Many prisoners in all three prisons also expressed concerns relating to the lack of 
water in their cells, a problem that might also explain why some methadone-prisoners 
did not take showers since they ran out of water in their units. A prisoner from the 
narcotics methadone prison described:
”I hope they give  more attention to our cell conditions, for example, we used 
to sleep very close to each other without space for moving;  there was no 
water in the toilet inside our cell and, so, we had to take water from a tap 
outside our cell every day” 
(Narcotics methadone prison, Non-methadone prisoner, late 20s).
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Discussion
To our knowledge, this is the first qualitative study that has explored the facilitators 
and barriers to the delivery of prison methadone programmes in Indonesian prisons, 
and one of the few on this topic overall. The facilitators and barriers to the delivery 
were clearly presented by using the  socio-ecological model (SEM). The study involved 
a wide range of prison stakeholders including prison governors, prison officers, 
healthcare staff, and prisoners. 
Our findings indicate that the methadone programmes in Indonesian prisons have 
benefited both prison staff and prisoners. These findings are in line with other studies 
that report a reduction in drug-related risk behaviours among prisoners as well as  
improvements in prisoners’ overall physical, social, financial and mental wellbeing 
where such programmes are introduced (Zamani et al. 2010; Moradi et al. 2015; 
Larney et al. 2017; Grella et al. 2020).
The current study found that unlike prisoners, most prison staff, including healthcare 
staff in all three study prisons, considered that HIV transmission was no longer a 
problem in prisons. This perception contrasts with the evidence that HIV transmission 
is more common in prison settings because of the much higher frequency of sharing 
injecting equipment (Culbert et al. 2015; Indig et al. 2010; Jürgens et al. 2009). 
Furthermore, this association has been reported (Dolan et al. 2015) both for prisons 
situated in high-income countries (Lindblom et al. 2017) and for middle-income 
countries including Indonesia (Sawitri et al. 2016).
In common with other studies (Stöver and Kastelic 2016, Komalasari et al.  2020; 
Komalasari et al. 2021), this study found considerable misunderstandings relating to 
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the use of methadone programmes as part of an HIV harm reduction strategy among 
both prison staff and prisoners and across all three study prisons. The idea that 
methadone is simply another type of illicit drug, was prevalent among most prison 
office s and some healthcare staff, again across all three prisons.  This has also been 
found in other prison-based studies (Carlin 2005; Asher 2013) leading prison staff and 
authorities to conclude that methadone programmes are not appropriate in prison 
settings (Stöver and Kastelic 2016; Mear et al. 2003). In contrast, Rieckman et al. 
(2010) reported a link between a better understanding of methadone programmes and 
reduced institutional resistance to prison-based methadone programmes. 
Many prisoners in both methadone prisons indicated that they feared methadone 
withdrawal intensely. They considered it to be much more dangerous than heroin 
withdrawal and even potentially fatal. These notions presented considerable barriers 
to programme participation. In Indonesian society, death is often very visible. 
However, the practice of leaving corpses temporarily in the prison clinic corridor, often 
for reasons linked to a lack of prison resources, troubled many prisoners greatly. 
Prisoners in all three study prisons spoke about the trauma of seeing the death of 
other prisoners and their families’ grief and associated it with their own eventual 
deaths. Similar findings have been reported by Loeb et al. (2014). 
In keeping with work on ‘risk environments’ (Rhodes 2002), greater flexibility in 
treatment processes could increase access to OAT programmes and prisoner 
participation. However, difficulties in accessing OAT programmes were clearly 
illustrated in the narcotics methadone prison, by the requirement for family consent 
prior to a prisoner’s participation. Many drug users are estranged from their families, 
or their drug-using history may not be known to their families. This requirement 
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suggests a lack of recognition of the personal circumstances of many prisoners who 
use drugs and that greater flexibility might increase participation. This study also found 
that restrictive clinic opening times contributed to methadone diversion and to high-
risk behaviours. Those who missed the clinic would ask for methadone from other 
methadone-prisoners or take illicit drugs, potentially leading to an increased risk of 
deaths from methadone overdose (Strang et al. 2005).
This study also indicated difficulties posed by the lack of flexibility in clinic opening 
times and requirements for daily clinic attendance as reported in previous studies 
(Sander et al. 2016; Mukherjee et al. 2016). This inflexibility could also exacerbate 
mental health problems commonly experienced by drug users, including anxiety and 
insomnia (also see Ross et al. 2015). This was particularly problematic when clinic 
times clashed with work programme times. Making some money by working was 
especially important for prisoners who were estranged from their families or had little 
family support. This finding has not been reported in other studies but it is critical to 
the experience of prisoners in lower/middle income countries.
In the Indonesian context, incorporating family support and education can play an 
essential role in shaping programmes and increasing prisoner participation and 
programme effectiveness. For example, education of family members about OAT 
programmes may increase prisoner participation by encouraging them to provide 
consent, financial support and to help the prisoners maintain abstinence from illicit 
drugs when in prison. In more general terms, the assessment processes adopted, 
which included sensitive questions on risk behaviours and urine drug-testing, may also 
deter participation.
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Full and proper consideration of institutional factors is an essential part of any harm 
reduction strategy. The shortage of prison officers, particularly those with adequate 
training in drug use and addiction, also contributed to methadone diversion which can 
lead to methadone withdrawal or potential overdoses of illicit drugs. There was also a 
shortage of healthcare staff after office hours, which contributed to and reinforced 
fears about methadone withdrawal among prisoners.
Alongside drug treatment, it has also been recommended that OAT programmes 
include psychosocial support and provide education, notably about how to manage 
withdrawal symptoms (Schuckit 2016; Greer et al. 2016). A number of studies 
(European Monitoring Centre for Drugs and Drug Addiction 2016; Jhanjee 2014) have 
reported negative impacts resulting from the lack of psycho-social support for OAT 
programme participants. These impacts included undermining the commitment to 
changing behaviour, difficulties in achieving drug reduction or drug abstinence and 
deterioration in physical and mental health. Specific training for healthcare staff should 
therefore promote understanding of the evidence base for substitution treatment 
(Thomas and Miller 2007) and the management of drug dependence and mental 
health problems (Ross et al. 2015). The link between insufficient information about 
OAT and low satisfaction with OAT, particularly methadone programmes, has also 
been reported in community settings in Vietnam, another middle-income country (Tran 
et al. 2012).
Poor prison conditions, including a lack of healthcare services linked to an increased 
risk of HIV infection, have also been reported in other low income prison contexts, for 
example Zambia (Simooya 2010). Elsewhere, improved management of prison 
facilities has long been associated with improved efforts to promote a supportive 
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environment for prisoners’ health and to protect prisoners’ human rights (Baybutt et al. 
2014; WHO 2005). 
Conclusion
This study uses the social ecological model to structure findings about facilitators of 
and barriers to the delivery of methadone programmes. The model highlights the 
importance of organisational and inter-personal as well as intrapersonal factors. Such 
an approach is particularly important in the context of the implementation and delivery 
of methadone programmes in lower/middle income countries, where socio-structural 
factors, as our study has shown, are so significant. It should also be noted that these 
groups of factors overlap. Overall, many more barriers than facilitators were identified. 
The SEM model also highlights the need to address barriers to the delivery of 
methadone programmes in prisons at these different levels - intrapersonal, inter-
personal and organisational. Therefore, three main strategies for  improvement were 
suggested: i) the development of a comprehensive education programme for prisoners 
and training programme for all staff, not only healthcare staff but prison officers and 
senior management as well. Such programmes would, for example, increase 
understanding of the role of harm reduction programmes; ii) the re-assessment of 
practices relating to the delivery of methadone (admission, dispensing practices), 
which would include conducting a comprehensive review of harm reduction strategies 
in prisons and elaborating the role of family in increasing support for prisoner 
participation, for example, by giving the family members education on harm reduction 
strategies; iii) the re-assessment of prison policy to support the delivery of methadone 
programmes in prisons, for example, by providing psychosocial support services for 
methadone participants.
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